Dianthus Therapeutics (DNTH) News Today $17.85 +0.17 (+0.96%) Closing price 04:00 PM EasternExtended Trading$17.84 -0.01 (-0.03%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.2% - What's Next?Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.2% - Should You Sell?May 29 at 4:16 PM | marketbeat.comDianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare ConferenceMay 29 at 7:00 AM | globenewswire.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of "Buy" from BrokeragesShares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have earned an average recommendation of "Buy" from the nine analysts that are currently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and two have issued a strongMay 27 at 1:16 AM | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Woodline Partners LPWoodline Partners LP raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 20.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 300,504 shares of the company's stock after purchasing an addiMay 26 at 4:37 AM | marketbeat.comDianthus Therapeutics appoints new board memberMay 24, 2025 | investing.comNorthern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Northern Trust Corp raised its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 21.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,523 shares of the company'sMay 23, 2025 | marketbeat.comDianthus Therapeutics Appoints Simon Read, Ph.D., to Board of DirectorsMay 22, 2025 | globenewswire.comPoint72 Asset Management L.P. Reduces Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Point72 Asset Management L.P. lessened its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 55.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 193,600 shares of the companMay 22, 2025 | marketbeat.comVestal Point Capital LP Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Vestal Point Capital LP grew its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 172.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,075,000 shares of the company's stock after buying an additioMay 21, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Holdings Lifted by Janus Henderson Group PLCJanus Henderson Group PLC lifted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 14.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,085,648 shares of the company's stock after buying an additional 136,314 shaMay 18, 2025 | marketbeat.comRobert W. Baird Has Lowered Expectations for Dianthus Therapeutics (NASDAQ:DNTH) Stock PriceRobert W. Baird cut their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday.May 15, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday.May 15, 2025 | marketbeat.comOctagon Capital Advisors LP Raises Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Octagon Capital Advisors LP raised its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 20.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,110,167 shares of the company's stock after buMay 15, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings ResultsDianthus Therapeutics (NASDAQ:DNTH - Get Free Report) released its earnings results on Monday. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%.May 14, 2025 | marketbeat.com4DNTH : Breaking Down Dianthus Therapeutics: 5 Analysts Share Their ViewsMay 13, 2025 | benzinga.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial ResultsMay 12, 2025 | globenewswire.comBraidwell LP Raises Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Braidwell LP grew its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 144.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,206,589 shares of the company's stock after acquiring an additional 712,902 sharesMay 8, 2025 | marketbeat.comDianthus Therapeutics completes enrollment for MaGic trialMay 6, 2025 | investing.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Avidity Partners Management LPAvidity Partners Management LP lessened its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 1.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,873,000 shares of the company's stock after sMay 6, 2025 | marketbeat.comDianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in SeptemberMay 5, 2025 | globenewswire.comAllostery Investments LP Takes Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Allostery Investments LP bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 25,000 shares of the company's stock, valued at approximatelyMay 4, 2025 | marketbeat.comAlly Bridge Group NY LLC Buys New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Ally Bridge Group NY LLC purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 106,434 shares of the company's stoMay 4, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) is 5AM Venture Management LLC's 6th Largest Position5AM Venture Management LLC reduced its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 16.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,027,711 shares of the company's stocMay 4, 2025 | marketbeat.comRA Capital Management L.P. Sells 466,600 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)RA Capital Management L.P. lowered its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 20.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,866,400 shares of the company's stock after selMay 3, 2025 | marketbeat.comDianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on ThursdayDianthus Therapeutics (NASDAQ:DNTH) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-dianthus-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Buy" by BrokeragesShares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been assigned a consensus rating of "Buy" from the nine analysts that are covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to tMay 3, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Buys Shares of 180,000 Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Adage Capital Partners GP L.L.C. purchased a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 180,000 sharMay 2, 2025 | marketbeat.comTCG Crossover Management LLC Acquires Shares of 1,501,624 Dianthus Therapeutics, Inc. (NASDAQ:DNTH)TCG Crossover Management LLC bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,501,624 shares of the company's stock, valuMay 1, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's What HappenedDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's WhyApril 30, 2025 | marketbeat.comDianthus Therapeutics to Participate in Two Upcoming Investor EventsApril 29, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.4% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Trading 7.4% Higher - What's Next?April 23, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Bain Capital Life Sciences Investors LLCBain Capital Life Sciences Investors LLC lowered its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 10.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,689,707 shares of the company's stock afteApril 23, 2025 | marketbeat.comWalleye Capital LLC Buys 52,890 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Walleye Capital LLC lifted its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 176.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 82,890 shares of the company's stock after acquiring an additional 52,890 sharApril 21, 2025 | marketbeat.comFmr LLC Buys 36,133 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Fmr LLC lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 0.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,439,281 shares of the company's stock after purchasing an additional 36April 18, 2025 | marketbeat.comVanguard Group Inc. Sells 20,331 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Vanguard Group Inc. lessened its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 1.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,274,638 shares of the company's stock after selling 20,331 shares during the quApril 16, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by ADAR1 Capital Management LLCADAR1 Capital Management LLC decreased its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 85.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 17,683 shares of the company's stock after seApril 9, 2025 | marketbeat.comAlliancebernstein L.P. Has $25.28 Million Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Alliancebernstein L.P. boosted its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 13.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,159,776 shares of the company's stock after acquiring anApril 9, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Rhenman & Partners Asset Management ABRhenman & Partners Asset Management AB lowered its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 24.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 114,000 shares of the coApril 7, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Buy" from BrokeragesDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has received an average recommendation of "Buy" from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and two have issued aApril 7, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase - Still a Buy?Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume - Should You Buy?April 4, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week Low - Should You Sell?Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 1-Year Low - Here's What HappenedApril 2, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 7% - Here's What HappenedDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 7% - Here's WhyApril 1, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Up 6.5% - Should You Buy?Dianthus Therapeutics (NASDAQ:DNTH) Trading 6.5% Higher - Here's WhyMarch 28, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week Low - What's Next?Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year Low - Here's What HappenedMarch 27, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.8% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8% - Here's What HappenedMarch 18, 2025 | marketbeat.comFY2025 EPS Estimates for DNTH Raised by Cantor FitzgeraldDianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for Dianthus Therapeutics in a research note issued to investors on Thursday, March 13th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the cMarch 17, 2025 | marketbeat.comHC Wainwright Issues Optimistic Outlook for DNTH EarningsDianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Dianthus Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst S. Ramakanth now forecMarch 17, 2025 | marketbeat.comWhat is Lifesci Capital's Estimate for DNTH FY2025 Earnings?Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at Lifesci Capital increased their FY2025 earnings estimates for shares of Dianthus Therapeutics in a research note issued to investors on Wednesday, March 12th. Lifesci Capital analyst R. Katkhuda now expects that the coMarch 15, 2025 | marketbeat.comWedbush Analysts Decrease Earnings Estimates for DNTHDianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at Wedbush decreased their Q1 2025 EPS estimates for shares of Dianthus Therapeutics in a research note issued on Wednesday, March 12th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.74) per sharMarch 15, 2025 | marketbeat.comStifel maintains Buy rating on Dianthus Therapeutics stockMarch 14, 2025 | uk.investing.com Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address DNTH Media Mentions By Week DNTH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNTH News Sentiment▼1.220.87▲Average Medical News Sentiment DNTH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNTH Articles This Week▼73▲DNTH Articles Average Week Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ImmunityBio News Xenon Pharmaceuticals News Amneal Pharmaceuticals News HUTCHMED News Organon & Co. News Mirum Pharmaceuticals News Apellis Pharmaceuticals News Arrowhead Pharmaceuticals News Vericel News NewAmsterdam Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNTH) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
